Is Humacyte (HUMA) Using Middle East Partnerships To Reframe Its Capital and Market Access Strategy? [Yahoo! Finance]
Humacyte, Inc. (HUMA)
Company Research
Source: Yahoo! Finance
a clinical evaluation and outreach program in Saudi hospitals, while also filing a US$20 million registered direct common stock offering and submitting a Marketing Authorization Application for Symvess trauma use in Israel. Together, these moves point to a simultaneous push for Middle East market access and additional funding, as the company expands real-world evaluation and clinician training for Symvess in complex trauma care settings. Now we'll explore how this Saudi purchase commitment and broader Middle East push may influence Humacyte's existing investment narrative. Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. Humacyte Investment Narrative Recap To own Humacyte today, you need to believe Symvess can grow from a niche trauma graft into a meaningful commercial franchise while the company manages cash burn and dilution risk. The Saudi purc
Show less
Read more
Impact Snapshot
Event Time:
HUMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HUMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HUMA alerts
High impacting Humacyte, Inc. news events
Weekly update
A roundup of the hottest topics
HUMA
News
- Wall Street Analysts Think Humacyte, Inc. (HUMA) Is a Good Investment: Is It? [Yahoo! Finance]Yahoo! Finance
- Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026GlobeNewswire
- Humacyte, Inc. (HUMA) Submits Marketing Authorization Application in Israel for Symvess [Yahoo! Finance]Yahoo! Finance
- Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi ArabiaGlobeNewswire
- Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common StockGlobeNewswire
HUMA
Earnings
- 11/12/25 - Beat
HUMA
Sec Filings
- 3/24/26 - Form SCHEDULE
- 3/19/26 - Form 8-K
- 3/19/26 - Form 424B3
- HUMA's page on the SEC website